Search Within

Samuel Aaron Funt

  1. "Advanced Practice Providers"
Formats
  1. Meeting Abstract (2)
  2. Editorial (1)
  3. Journal Article (1)
Groups
  1. Advanced Practice Providers (4)
  2. Department of Medicine (4)
  3. Department of Pathology and Laboratory Medicine (4)
  4. Genitourinary Oncology Service (4)
  5. Nursing (4)
  6. Solid Tumor Oncology Division (4)

More Groups

People
  1. Andrea Knezevic (3)
  2. Darren Feldman (3)
  3. Deaglan McHugh (3)
  4. Dean Bajorin (3)
  5. Maryann Carousso (3)
  6. Brett Carver (2)

More People

Years
  1. 2023 (1)
  2. 2021 (1)
  3. 2019 (1)
  4. 2018 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. European Urology (1)
  3. The Oncologist (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. Elsevier Science, Inc. (1)
  3. Oxford University Press (1)

Results (4)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT)
    Meeting Abstract

    Funt, S. A.; Knezevic, A.; Freeman, B. A.; Bolos, M.; Martorana, V.; Donoghue, M.; Khan, S.; Singh, H.; Bromberg, M.; Quinlan, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Four cycles of etoposide plus cisplatin for patients with good-risk advanced germ cell tumors
    Journal Article

    Funt, S. A.; McHugh, D. J.; Tsai, S.; Knezevic, A.; O'Donnell, D.; Patil, S.; Silber, D.; Bromberg, M.; Carousso, M.; Reuter, V. E.; more...
    The Oncologist (2021)

    Fulltext@MSK | Save
  • Genomic differences between “primary” and “secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy
    Editorial

    Pietzak, E. J.; Zabor, E. C.; Bagrodia, A.; Armenia, J.; Hu, W.; Zehir, A.; Funt, S.; Audenet, F.; Barron, D.; Maamouri, N.; more...
    European Urology (2019)

    Fulltext@MSK | Save
  • Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts)
    Meeting Abstract

    Funt, S.; McHugh, D. J.; Tsai, S.; O'Donnell, D.; Knezevic, A.; Patil, S.; Silber, D.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save